Blog / Regulatory & CMC

Regulatory & CMC

Insights and perspectives from our team on industry trends and scientific advances.

CMC Regulatory Dossiers for Nanomedicines: Module 3 Deep Dive

CMC Regulatory Dossiers for Nanomedicines: Module 3 Deep Dive

Why Standard Module 3 Templates Fall Short for Nanomedicines The Common Technical Document (CTD) Module 3 template was designed for conventional small molecule and biological drug products. For nanomedicine products, including lipid nanoparticles, polymeric nanoparticles, and metal oxide nanoparticle systems, the template provides a useful framework but cannot accommodate the full complexity of the characterization […]

Read more May 25, 2026
ICH M10 Compliance: What the Bioanalytical Guideline Means in Practice

ICH M10 Compliance: What the Bioanalytical Guideline Means in Practice

The Guideline That Harmonized Global Bioanalysis Before ICH M10, bioanalytical method validation was governed by separate guidance documents from the FDA and EMA that, while broadly aligned, differed in specific requirements for acceptance criteria, validation parameters, and reporting expectations. A study submitted to both agencies might require two slightly different validation packages, creating additional work […]

Read more May 25, 2026
Handling Controlled Substances in Clinical Trials

Handling Controlled Substances in Clinical Trials

A Growing Category in Drug Development Controlled substances have moved from the margins of pharmaceutical development to its center. Psychedelic-assisted therapy programs involving psilocybin, MDMA, and ketamine derivatives are advancing through Phase II and Phase III trials. Cannabis-derived medicines, opioid alternatives, and GABA-modulating compounds for neurological conditions all involve scheduled molecules. The renaissance of interest […]

Read more May 24, 2026
Bridging Studies: Changing Formulations Mid-Clinical Trial

Bridging Studies: Changing Formulations Mid-Clinical Trial

Formulation Change Is Inevitable It is the rare pharmaceutical development program that reaches Phase III with exactly the same formulation that entered Phase I. Scale-up changes, stability-driven modifications, bioavailability improvements, and the practical realities of manufacturing optimization all result in formulation differences between the early clinical and the intended commercial product. This is not a […]

Read more May 24, 2026